Traders Buy High Volume of Call Options on ImmunoPrecise Antibodies (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) was the recipient of unusually large options trading on Wednesday. Traders bought 3,524 call options on the company. This represents an increase of approximately 6,193% compared to the typical volume of 56 call options.

ImmunoPrecise Antibodies Stock Up 60.2 %

ImmunoPrecise Antibodies stock traded up $0.30 during midday trading on Wednesday, hitting $0.79. 246,571,867 shares of the stock were exchanged, compared to its average volume of 18,194,236. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85. The company has a 50 day moving average price of $0.44 and a two-hundred day moving average price of $0.60. The firm has a market cap of $24.54 million, a P/E ratio of -0.97 and a beta of 0.01. ImmunoPrecise Antibodies has a 1 year low of $0.32 and a 1 year high of $2.60.

ImmunoPrecise Antibodies (NASDAQ:IPA) last issued its quarterly earnings results on Tuesday, December 10th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. On average, sell-side analysts predict that ImmunoPrecise Antibodies will post -0.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price objective on shares of ImmunoPrecise Antibodies from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th.

Institutional Trading of ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC grew its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,558,892 shares of the company’s stock after purchasing an additional 263,451 shares during the period. Ingalls & Snyder LLC owned 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.